Kyntra Bio (KYNB) vs Polyrizon (PLRZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polyrizon (PLRZ) has outperformed Kyntra Bio (KYNB) over the past year, gaining 23.2% versus a loss of 47.7%. Kyntra Bio is the larger company by market cap ($24.1 million vs $21.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYNB | PLRZ |
|---|---|---|
| Share price | $5.96 | $8.87 |
| Market cap | $24.13M | $21.54M |
| 1-day change | -1.32% | -3.06% |
| YTD return | -32.12% | +4.48% |
| 1-year return | -47.72% | +23.19% |
| 5-year return | -97.84% | — |
| EPS (TTM) | $-7.64 | $-4.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.65 | $18.20 |
| 52-week low | $5.62 | $2.88 |
| Distance from 52-week high | -48.84% | -51.26% |
| Analyst consensus | none | — |
| Avg. price target upside | +565.60% | — |
| Average volume | 18.29K | 60.55K |
| Shares outstanding | 4.05M | 2.43M |
| Employees | 34 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRZ has outperformed KYNB by 70.9 percentage points over the past year.
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Healthcare · Biotechnology · 34 employees
About Polyrizon
PLRZ stock →Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Healthcare · Biotechnology · 2 employees
KYNB vs PLRZ FAQ
Which is bigger, Kyntra Bio or Polyrizon?
Kyntra Bio (KYNB) is larger, with a market capitalization of $24.13M compared with $21.54M for Polyrizon (PLRZ).
Which stock has performed better over the past year, KYNB or PLRZ?
PLRZ returned +23.19% over the past 12 months, compared with -47.72% for KYNB (price return, excluding dividends). Past performance does not predict future results.
Are Kyntra Bio and Polyrizon in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.